Changyan Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Changyan Ma has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
Yucui Jin
Department of Medical Genetics, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China
15 shared publicationsLingyun Li
Department of Medical Genetics Nanjing Medical University Nanjing China
12 shared publicationsYuting Tang
Department of Medical Genetics, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China
11 shared publicationsMing Zhang
Department of Medical Genetics, School of Basic Medical Sciences, Nanjing Medical University, 101 Longmian Avenue, Nanjing, 211166, China; Department of Reproductive Genetic Center, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School of Nanjing Medical University, China
10 shared publicationsBing Yao
Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical University, Nanjing, China
9 shared publicationsHongyan Yuan
Department of Oncology and Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, 20007, USA
9 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Breaking the immune barrier: construction of cartilaginous organoids using alpha-1,3-galactosyltransferase-deficient pig cartilage-derived particles
Articular cartilage injuries exhibit limited self-repair capacity due to avascularity and other intrinsic properties, leading to high disability rates and
- 3 June 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessBreaking the immune barrier: construction of cartilaginous organoids using alpha-1,3-galactosyltransferase-deficient pig cartilage-derived particles
Articular cartilage injuries exhibit limited self-repair capacity due to avascularity and other intrinsic properties, leading to high disability rates and
- 22 November 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (7) , e03687
Regulation of Inflammatory and Metabolic Microenvironment With a D‐Mannose Functionalized Hydrogel for Improved Osteochondral Regeneration
Endogenous regenerative strategy for osteochondral defect (OCD) repair remains challenging, largely due to the need to regulate the local inflammatory and metabolic microenvironment while preserving the stemness of bone marrow mesenchymal stem cells (BMSCs). Here, D‐mannose we identify as a potent immunometabolic modulator that enhances BMSC‐mediated osteochondral repair. Through in vitro experiments, we determined the optimal concentration of D‐mannose and evaluated its ability to preserve the osteogenic and chondrogenic differentiation potential of BMSCs under inflammatory microenvironment. Transcriptomic analysis demonstrated that D‐mannose contributed to the amelioration of inflammation by downregulating the NLRP3 inflammasome pathway. The metabolomic analysis further revealed that D‐mannose treatment alleviated inflammation‐induced dysregulation of the tricarboxylic acid cycle and facilitated the maintenance of glycolytic metabolic state in BMSCs. Furthermore, we fabricated a multifunctional GelMA‐based hydrogel incorporating D‐mannose (DM@GelMA). Macroscopic observation, micro‐CT analysis and histological evaluation confirmed that DM@GelMA hydrogel effectively promoted osteochondral tissue remodeling and integration in the OCD model of rats. These findings suggested that the multifunctional D‐mannose‐loaded composite hydrogel is a promising biomaterial for enhanced osteochondral regeneration.
- 22 November 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (7) , e03687
Regulation of Inflammatory and Metabolic Microenvironment With a D‐Mannose Functionalized Hydrogel for Improved Osteochondral Regeneration
Endogenous regenerative strategy for osteochondral defect (OCD) repair remains challenging, largely due to the need to regulate the local inflammatory and metabolic microenvironment while preserving the stemness of bone marrow mesenchymal stem cells (BMSCs). Here, D‐mannose we identify as a potent immunometabolic modulator that enhances BMSC‐mediated osteochondral repair. Through in vitro experiments, we determined the optimal concentration of D‐mannose and evaluated its ability to preserve the osteogenic and chondrogenic differentiation potential of BMSCs under inflammatory microenvironment. Transcriptomic analysis demonstrated that D‐mannose contributed to the amelioration of inflammation by downregulating the NLRP3 inflammasome pathway. The metabolomic analysis further revealed that D‐mannose treatment alleviated inflammation‐induced dysregulation of the tricarboxylic acid cycle and facilitated the maintenance of glycolytic metabolic state in BMSCs. Furthermore, we fabricated a multifunctional GelMA‐based hydrogel incorporating D‐mannose (DM@GelMA). Macroscopic observation, micro‐CT analysis and histological evaluation confirmed that DM@GelMA hydrogel effectively promoted osteochondral tissue remodeling and integration in the OCD model of rats. These findings suggested that the multifunctional D‐mannose‐loaded composite hydrogel is a promising biomaterial for enhanced osteochondral regeneration.
- 19 July 2025
- Published by Elsevier in Cancer Letters
- Vol. 631, 217939
NSUN2-mediated m5C modification of KDM6B mRNA enhances osteoclast differentiation and promotes breast cancer bone metastasis
- 19 July 2025
- Published by Elsevier in Cancer Letters
- Vol. 631, 217939
NSUN2-mediated m5C modification of KDM6B mRNA enhances osteoclast differentiation and promotes breast cancer bone metastasis
- Open Access
- 5 July 2024
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (7) , e1753
KMT2D‐mediated H3K4me1 recruits YBX1 to facilitate triple‐negative breast cancer progression through epigenetic activation of c‐Myc
Background: Lysine methyltransferase 2D (KMT2D) mediates mono‐methylation of histone H3 lysine 4 (H3K4me1) in mammals. H3K4me1 mark is involved in establishing an active chromatin structure to promote gene transcription. However, the precise molecular mechanism underlying the KMT2D‐mediated H3K4me1 mark modulates gene expression in triple‐negative breast cancer (TNBC) progression is unresolved.Methods and Results: We recognized Y‐box‐binding protein 1 (YBX1) as a “reader” of the H3K4me1 mark, and a point mutation of YBX1 (E121A) disrupted this interaction. We found that KMT2D and YBX1 cooperatively promoted cell growth and metastasis of TNBC cells in vitro and in vivo. The expression levels of KMT2D and YBX1 were both upregulated in tumour tissues and correlated with poor prognosis for breast cancer patients. Combined analyses of ChIP‐seq and RNA‐seq data indicated that YBX1 was co‐localized with KMT2D‐mediated H3K4me1 in the promoter regions of c‐Myc and SENP1, thereby activating their expressions in TNBC cells. Moreover, we demonstrated that YBX1 activated the expressions of c‐Myc and SENP1 in a KMT2D‐dependent manner.Conclusion: Our results suggest that KMT2D‐mediated H3K4me1 recruits YBX1 to facilitate TNBC progression through epigenetic activation of c‐Myc and SENP1. These results together unveil a crucial interplay between histone mark and gene regulation in TNBC progression, thus providing novel insights into targeting the KMT2D‐H3K4me1‐YBX1 axis for TNBC treatment.Highlights: YBX1 is a KMT2D‐mediated H3K4me1‐binding effector protein and mutation of YBX1 (E121A) disrupts its binding to H3K4me1. KMT2D and YBX1 cooperatively promote TNBC proliferation and metastasis by activating c‐Myc and SENP1 expression in vitro and in vivo. YBX1 is colocalized with H3K4me1 in the c‐Myc and SENP1 promoter regions in TNBC cells and increased YBX1 expression predicts a poor prognosis in breast cancer patients.
- 5 July 2024
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (7) , e1753
Open AccessKMT2D‐mediated H3K4me1 recruits YBX1 to facilitate triple‐negative breast cancer progression through epigenetic activation of c‐Myc
Background: Lysine methyltransferase 2D (KMT2D) mediates mono‐methylation of histone H3 lysine 4 (H3K4me1) in mammals. H3K4me1 mark is involved in establishing an active chromatin structure to promote gene transcription. However, the precise molecular mechanism underlying the KMT2D‐mediated H3K4me1 mark modulates gene expression in triple‐negative breast cancer (TNBC) progression is unresolved.Methods and Results: We recognized Y‐box‐binding protein 1 (YBX1) as a “reader” of the H3K4me1 mark, and a point mutation of YBX1 (E121A) disrupted this interaction. We found that KMT2D and YBX1 cooperatively promoted cell growth and metastasis of TNBC cells in vitro and in vivo. The expression levels of KMT2D and YBX1 were both upregulated in tumour tissues and correlated with poor prognosis for breast cancer patients. Combined analyses of ChIP‐seq and RNA‐seq data indicated that YBX1 was co‐localized with KMT2D‐mediated H3K4me1 in the promoter regions of c‐Myc and SENP1, thereby activating their expressions in TNBC cells. Moreover, we demonstrated that YBX1 activated the expressions of c‐Myc and SENP1 in a KMT2D‐dependent manner.Conclusion: Our results suggest that KMT2D‐mediated H3K4me1 recruits YBX1 to facilitate TNBC progression through epigenetic activation of c‐Myc and SENP1. These results together unveil a crucial interplay between histone mark and gene regulation in TNBC progression, thus providing novel insights into targeting the KMT2D‐H3K4me1‐YBX1 axis for TNBC treatment.Highlights: YBX1 is a KMT2D‐mediated H3K4me1‐binding effector protein and mutation of YBX1 (E121A) disrupts its binding to H3K4me1. KMT2D and YBX1 cooperatively promote TNBC proliferation and metastasis by activating c‐Myc and SENP1 expression in vitro and in vivo. YBX1 is colocalized with H3K4me1 in the c‐Myc and SENP1 promoter regions in TNBC cells and increased YBX1 expression predicts a poor prognosis in breast cancer patients.
- Open Access
- 28 November 2023
- Published by Wiley in Advanced Science
- Vol. 11 (2) , e2302037
EBF2 Links KMT2D‐Mediated H3K4me1 to Suppress Pancreatic Cancer Progression via Upregulating KLLN
Mono‐methylation of histone H3 on Lys 4 (H3K4me1), which is catalyzed by histone‐lysine N‐methyltransferase 2D (KMT2D), serves as an important epigenetic regulator in transcriptional control. In this study, the authors identify early B‐cell factor 2 (EBF2) as a binding protein of H3K4me1. Combining analyses of RNA‐seq and ChIP‐seq data, the authors further identify killin (KLLN) as a transcriptional target of KMT2D and EBF2 in pancreatic ductal adenocarcinoma (PDAC) cells. KMT2D‐dependent H3K4me1 and EBF2 are predominantly over‐lapped proximal to the transcription start site (TSS) of KLLN gene. Comprehensive functional assays show that KMT2D and EBF2 cooperatively inhibit PDAC cells proliferation, migration, and invasion through upregulating KLLN. Such inhibition on PDAC progression is also achieved through increasing H3K4me1 level by GSK‐LSD1, a selective inhibitor of lysine‐specific demethylase 1 (LSD1). Taken together, these findings reveal a new mechanism underlying PDAC progression and provide potential therapeutic targets for PDAC treatment.
- 28 November 2023
- Published by Wiley in Advanced Science
- Vol. 11 (2) , e2302037
Open AccessEBF2 Links KMT2D‐Mediated H3K4me1 to Suppress Pancreatic Cancer Progression via Upregulating KLLN
Mono‐methylation of histone H3 on Lys 4 (H3K4me1), which is catalyzed by histone‐lysine N‐methyltransferase 2D (KMT2D), serves as an important epigenetic regulator in transcriptional control. In this study, the authors identify early B‐cell factor 2 (EBF2) as a binding protein of H3K4me1. Combining analyses of RNA‐seq and ChIP‐seq data, the authors further identify killin (KLLN) as a transcriptional target of KMT2D and EBF2 in pancreatic ductal adenocarcinoma (PDAC) cells. KMT2D‐dependent H3K4me1 and EBF2 are predominantly over‐lapped proximal to the transcription start site (TSS) of KLLN gene. Comprehensive functional assays show that KMT2D and EBF2 cooperatively inhibit PDAC cells proliferation, migration, and invasion through upregulating KLLN. Such inhibition on PDAC progression is also achieved through increasing H3K4me1 level by GSK‐LSD1, a selective inhibitor of lysine‐specific demethylase 1 (LSD1). Taken together, these findings reveal a new mechanism underlying PDAC progression and provide potential therapeutic targets for PDAC treatment.
- 5 September 2023
- Published by Springer Nature in Cytotechnology
- Vol. 75 (6) , 505-516
MiR-224-5p inhibits osteoblast differentiation and impairs bone formation by targeting Runx2 and Sp7
Osteoporosis is a complicated multifactorial disorder characterized by low bone mass and deteriorated bone microarchitecture with an elevated fracture risk. MicroRNAs play important roles in osteoblastic differentiation. In the present study, we found that miR-224-5p was markedly downregulated during the osteogenic differentiation of C2C12 cells. Overexpression of miR-224-5p in C2C12 cells inhibited osteoblast activity, as indicated by reduced ALP activity, matrix mineralization and the expression of osteogenic marker genes. Moreover, we demonstrated that Runx2 and Sp7 were direct targets of miR-224-5p. Furthermore, the specific inhibition of miR-224-5p by femoral bone marrow cavity injection with miR-224-5p antagomir prevented ovariectomy-induced bone loss. Finally, we found that the levels of miR-224-5p were markedly elevated in the sera of patients with osteoporosis. Collectively, this study revealed that miR-224-5p negatively regulates osteogenic differentiation by targeting Runx2 and Sp7. It also highlights the potential use of miR-224-5p as a therapeutic target and diagnostic biomarker for osteoporosis.
- 5 September 2023
- Published by Springer Nature in Cytotechnology
- Vol. 75 (6) , 505-516
MiR-224-5p inhibits osteoblast differentiation and impairs bone formation by targeting Runx2 and Sp7
Osteoporosis is a complicated multifactorial disorder characterized by low bone mass and deteriorated bone microarchitecture with an elevated fracture risk. MicroRNAs play important roles in osteoblastic differentiation. In the present study, we found that miR-224-5p was markedly downregulated during the osteogenic differentiation of C2C12 cells. Overexpression of miR-224-5p in C2C12 cells inhibited osteoblast activity, as indicated by reduced ALP activity, matrix mineralization and the expression of osteogenic marker genes. Moreover, we demonstrated that Runx2 and Sp7 were direct targets of miR-224-5p. Furthermore, the specific inhibition of miR-224-5p by femoral bone marrow cavity injection with miR-224-5p antagomir prevented ovariectomy-induced bone loss. Finally, we found that the levels of miR-224-5p were markedly elevated in the sera of patients with osteoporosis. Collectively, this study revealed that miR-224-5p negatively regulates osteogenic differentiation by targeting Runx2 and Sp7. It also highlights the potential use of miR-224-5p as a therapeutic target and diagnostic biomarker for osteoporosis.
- Open Access
- 23 August 2023
- Published by Walter de Gruyter GmbH in Oncologie
- Vol. 25 (6) , 681-690
DUSP1 promotes pancreatic cancer cell proliferation and invasion by upregulating nephronectin expression
Objectives: To explore the role of dual-specific phosphatase 1 (DUSP1) in the proliferation, migration and invasion of pancreatic cancer (PC). Methods: TCGA and GTEx databases were used to investigate the relationship between DUSP1 expression and prognosis of PC patients. Expression efficiency of DUSP1 was validated by qPCR and western blotting. The proliferation of SW1990 and PANC-1 cells with DUSP1 overexpression or knockout was detected by EdU assays. The migratory and invasive abilities of cells were detected by wound healing and transwell assays. Results: DUSP1 was highly expressed in PC and associated with poor prognosis of patients. Overexpression of DUSP1 promoted the proliferation, migration and invasion of PC cells by regulating nephronectin (NPNT), whereas knockout of DUSP1 exhibited the opposite effects. NPNT expression was positively correlated with DUSP1, and the overall survival of PC patients with high levels of NPNT was shorter. Conclusions: DUSP1 promoted the proliferation, migration and invasion of PC cells by upregulating NPNT, suggesting DUSP1 may be a potential target for PC treatment.
- 23 August 2023
- Published by Walter de Gruyter GmbH in Oncologie
- Vol. 25 (6) , 681-690
Open AccessDUSP1 promotes pancreatic cancer cell proliferation and invasion by upregulating nephronectin expression
Objectives: To explore the role of dual-specific phosphatase 1 (DUSP1) in the proliferation, migration and invasion of pancreatic cancer (PC). Methods: TCGA and GTEx databases were used to investigate the relationship between DUSP1 expression and prognosis of PC patients. Expression efficiency of DUSP1 was validated by qPCR and western blotting. The proliferation of SW1990 and PANC-1 cells with DUSP1 overexpression or knockout was detected by EdU assays. The migratory and invasive abilities of cells were detected by wound healing and transwell assays. Results: DUSP1 was highly expressed in PC and associated with poor prognosis of patients. Overexpression of DUSP1 promoted the proliferation, migration and invasion of PC cells by regulating nephronectin (NPNT), whereas knockout of DUSP1 exhibited the opposite effects. NPNT expression was positively correlated with DUSP1, and the overall survival of PC patients with high levels of NPNT was shorter. Conclusions: DUSP1 promoted the proliferation, migration and invasion of PC cells by upregulating NPNT, suggesting DUSP1 may be a potential target for PC treatment.